Drug Trial Radar · NCT06671470
A Drug-drug Interaction Study of YZJ-1139 Tablets and Ticagrelor Tablets in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Aug 22, 2024
Primary completion
Sep 13, 2024
Study completion Oct 15, 2024
Sponsor
- Lead sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Primary Objective : To evaluate the effect of ticagrelor tablets on the pharmacokinetic characteristics of YZJ-1139 in healthy subjects; Secondary Objective: To evaluate the safety of ticagrelor tablets in combination with YZJ-1139 tablets in healthy subjects.
Conditions
- Insomnia
Interventions
YZJ-1139 tabletsDrug
Oral dose 20 mg
Ticagrelor TabletsDrug
Oral dose 90 mg twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics of YZJ-1139(Cmax)Time frame: 48 hours
- Pharmacokinetics of YZJ-1139 (AUC0-∞)Time frame: 48 hours
- Pharmacokinetics of YZJ-1139 (AUC0-t)Time frame: 48 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shulan (Hangzhou) Hospital
Huangzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.